丹参酮ⅡA磺酸钠注射液辅助治疗肺动脉高压临床观察

Clinical Observation of Tanshinone IIA Sulfonic Acid Natrium Injection Adjuvant Therapy for Treatment of Pulmonary Hypertension

目的:观察丹参酮ⅡA磺酸钠注射液辅助治疗肺动脉高压的临床疗效。方法:选择60例肺动脉高压患者,随机分为2组各30例,2组均采用常规西医疗法,观察组予丹参酮ⅡA磺酸钠注射液辅助治疗,比较2组的临床疗效,与治疗前后的6 min步行试验距离(6MWD)、Borg呼吸困难评分和平均肺动脉压(mPAP)。结果:临床疗效总有效率观察组为73.33%,对照组为46.67%,2组总有效率比较,差异有显著性意义(P<0.05)。治疗后,2组6MWD、Borg呼吸困难评分和mPAP均较治疗前改善(P<0.05);观察组6MWD大于对照组,mPAP、Borg呼吸困难评分均低于对照组,差异均有显著性意义(P<0.05)。结论:丹参酮ⅡA磺酸钠注射液辅助治疗肺动脉高压具有显著疗效,可明显改善患者的临床心功能状态,有利于延缓患者的病情发展,值得临床应用。

Objective. To investigate the therapeutic effect of tanshinone llA sulfonic acid natrium injection adjuvant therapy in the treatment of pulmonary hypertension. Methods： Sixty patients were randomly divided into observation group and control group, 30 cases in each group. Both groups were treated with conventional western medicine, and the observation group was given tanshinone IIA sulfonic acid natrium injection adjuvant therapy. The clinical effect, 6-minute walk distance（6MWD）, Borg dyspnea scores and mean pulmonary arterial pressure（mPAP）were observed before and after treatment. Results： The total effective rate was 73.33% in the observation group and was 46.67% in the control group, the difference being significant （P 〈0.05）. 6MWD, Borg dyspnea scores and mPAP were improved after treatment in both groups（P 〈 0.05 compared with those before treatment）. 6MWD, Borg dyspnoea scores and mPAP in the observation group were superior to those in the control group（P 〈 0.05）. Conclusion. Tanshinone IIA sulfonic acid natrium injection adjuvant therapy has certain effect on pulmonary hypertension by ameliorating heart function and postponing the development.